Patrys Limited (AU:PAB) has released an update.
Patrys Limited, an Australian biotechnology firm developing cancer therapies, has announced a delay in the completion of specification testing for its leading drug candidate, PAT-DX1, now expected in early October 2024. The testing is crucial for the drug’s release for use in clinical trials, and any delays could impact the timeline of clinical development activities. The company promises to keep stakeholders informed about any further changes to the schedule.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.
